Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Sep 1;123(17):3285-3290.
doi: 10.1002/cncr.30738. Epub 2017 Apr 25.

Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study

Eytan Ben-Ami  1 , Constance M Barysauskas  2 , Sarah Solomon  1 , Kadija Tahlil  1 , Rita Malley  1 , Melissa Hohos  1 , Kathleen Polson  1 , Margaret Loucks  1 , Mariano Severgnini  3 , Tara Patel  3 , Amy Cunningham  3 , Scott J Rodig  3   4 , F Stephen Hodi  3   5 , Jeffrey A Morgan  1 , Priscilla Merriam  1 , Andrew J Wagner  1 , Geoffrey I Shapiro  6   7 , Suzanne George  1
Affiliations
Clinical Trial

Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study

Eytan Ben-Ami et al. Cancer. .

Abstract

Background: Immunotherapy has changed the therapeutic landscape in oncology. Advanced uterine leiomyosarcoma (ULMS) remains an incurable disease in most cases, and despite new drug approvals, improvements in overall survival have been modest at best. The goal of this study was to evaluate programmed-death 1 (PD-1) inhibition with nivolumab in this patient population.

Methods: This single-center phase 2 trial completed enrollment between May and October 2015. Patients received 3 mg/kg of intravenous nivolumab on day 1 of each 2-week cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate. We assessed PD-1, PD-ligand 1 (PD-L1), and PD-L2 expression in archival tumor samples and variations in immune-phenotyping of circulating immune cells during treatment.

Results: Twelve patients were enrolled in the first stage of the 2-stage design. A median of 5 (range, 2-6) 2-week cycles of nivolumab were administered. Of the 12 patients, none responded to treatment. The overall median progression-free survival was 1.8 months (95% confidence interval, 0.8-unknown). The study did not open the second stage due to lack of benefit as defined by the statistical plan. Archival samples were available for 83% of patients. PD-1 (>3% of cells), PD-L1, and PD-L2 (>5% and >10% of tumor cells, respectively) expression were observed in 20%, 20%, and 90% of samples, respectively. No significant differences were observed between pre- and posttreatment cell phenotypes.

Conclusion: Single-agent nivolumab did not demonstrate a benefit in this cohort of previously treated advanced ULMS patients. Further biomarker-driven approaches and studies evaluating combined immune checkpoint-modulators should be considered. Cancer 2017;123:3285-90. © 2017 American Cancer Society.

Keywords: anti-programmed-death 1 (PD-1); immunotherapy; nivolumab; sarcoma; uterine leiomyosarcoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progression-free survival.
Figure 2
Figure 2
Overall survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
    1. Zivanovic O, Leitao M, Lasonos A, Lindsay M, Jacks Q, Abu Rustum N. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. J Clin Oncol. 2009;27:2066–2072. - PMC - PubMed
    1. Echt G, Jepson J, Steel J, et al. Treatment of uterine sarcomas. Cancer. 1990;66:35–39. - PubMed
    1. Gadducci A, Landoni F, Sartori E, et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol. 1996;62:25–32. - PubMed
    1. Salazar OM, Bonfiglio TA, Patten SF, et al. Uterine sarcomas: natural history, treatment and prognosis. Cancer. 1978;42:1152–1160. - PubMed

Publication types

MeSH terms